The Path Forward for CBD: Exploring the Journey to Legalize Hemp-Derived CBD

June 9, 2021 3:45pm

Shawn Hauser
Partner
Vicente Sederberg LLP (Denver, CO)

Douglas “Duffy” MacKay, N.D.
Senior Vice President Scientific & Regulatory Affairs
CV Sciences, Inc.
(San Diego, CA)

  • Learn about H.R. 841 – Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act
    • What became of H.R. 8179 in the last Congress?
    • What does the legislation actually do?
  • Understand the likelihood of FDA actions for CBD in the Biden Administration
    • Effect of FDA’s withdrawal of its Cannabidiol Enforcement Policy; Draft Guidance for Industry and release of its notice entitled “Better Data for a Better Understanding of the Use and Safety Profile of Cannabidiol (CBD) Products
  • Navigate the dangers of inconsistent state CBD laws in the absence of federal regulation
  • Assess the loss of potential revenue streams to industry resulting from this federal and state legal and regulatory conundrum
    • Weighing the risks of “sitting it out” vs. “going rogue”
  • Understand the unspoken connection between finalizing FDA’s NDIN draft guidance and creating a legal pathway for CBD
  • Consider how an NDI-only pathway for CBD could derail the economic intent of the Farm Bill